Key Dates

Related Announcements

• September 11, 2023 - Intervention Research to Improve Native American Health (R01 Clinical Trial Optional). See NOFO PAR-23-298.

Issued by

National Heart, Lung, and Blood Institute (NHLBI)

Purpose

The purpose of this Notice is to inform potential applicants that the NHLBI is participating, effective immediately, in PAR-23-298 Intervention Research to Improve Native American Health (R01 Clinical Trial Optional). 

The National Heart, Lung, and Blood Institute (NHLBI) supports research that tests culturally-appropriate and sustainable interventions to reduce cardiovascular, pulmonary, blood, or sleep-related disorders and associated morbidity and mortality across the lifespan. Interventions may address behaviors that adversely impact health and well-being, including but not limited to smoking, poor dietary behavior, physical inactivity, and poor sleep. Interventions that address health outcomes related to cardiovascular, pulmonary, blood, or sleep disorders, including but not limited to hypertension, dyslipidemia (elevated LDL, total cholesterol, and/or triglycerides), asthma, chronic obstructive pulmonary disease (COPD) and iron-deficiency anemia are encouraged. Applications are expected to include at least one or more social determinants of health in their proposals (see NIH’s PhenX Social Determinants of Health Assessments Collection).

Examples of projects of interest to NHLBI include, but are not limited to the following:

1. Primordial, primary, and secondary prevention of cardiovascular and pulmonary diseases and sleep disorders.
2. Strategies and interventions that may mitigate the impact of long-term effects of COVID-19 on heart, lung, blood, and sleep health.
3. Multi-level and multi-generational interventions of health risk factors, including psychosocial and behavioral factors that contribute to cardiovascular, pulmonary, and sleep related morbidity and mortality.
4. Strategies and/or interventions to accurately diagnose, treat, or prevent cardiovascular disease and its risk factors in women.
5. Multi-level and culturally-tailored interventions that target women at the preconception, prenatal, or postnatal period to promote cardiovascular and cardiopulmonary health of the mother and child.
6. Dietary, physical activity, and sleep interventions to promote cardiopulmonary and cardiometabolic health.
7. Intervention strategies to prevent or treat early childhood cardiometabolic or adult risk factors related to cardiovascular and pulmonary diseases.
8. Interventions that address vascular contributions to cognitive impairment and dementia. 
9. Strategies and interventions to prevent and/or treat obesity in children and adults, reduce the impact of diabetes-related cardiovascular disease, reduce the impact of cardiovascular and pulmonary disease that affect people living with HIV, or reduce the impact of alcohol use disorders on cardiovascular health.
10. Implementation research that evaluates proven modalities found effective in other population groups that may be tested and evaluated in Native populations using established theoretical frameworks (e.g., RE-AIM: Reach, Efficacy/Effectiveness, Adoption, Implementation, Maintenance).
11. Methods to enhance the dissemination and use of evidence-based resources (e.g., a toolkit for grocery store owners centered in Native communities, training sessions that help to address food justice, nutrition, physical activity, and/or health disparities) to promote cardiometabolic health and reduce health disparities.
12. Precision medicine-based interventions that use genomic data to address the high prevalence of cardiovascular, pulmonary, and sleep-related diseases and disorders.
13. Intervention approaches to address environmental exposures, including hotter temperatures and urban air, noise, and light pollution that may impact heart, lung, blood, and sleep disorders.
14. Artificial intelligence and machine learning algorithms to facilitate intervention and implementation strategies.

The following text (shown in italics) has been added to reflect NHLBI's participation in this NOFO:

Part 1. Overview Information

Components of Participating Organizations

National Heart, Lung, and Blood Institute (NHLBI) 

Catalog of Federal Domestic Assistance (CFDA) Number(s)

93.837, 93.838, 93.839, 93.840, 93.233 

Part 2. Section VII. Agency Contacts

Scientific/Research Contact(s)

Mona Puggal, MPH
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0704
Email: mona.puggal@nih.gov

Financial/Grants Management Contact(s)

Leslye Fulwider
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-480-9544
Email: leslye.fulwider@nih.gov

Inquiries

Please direct all inquiries to:

Scientific/Research Contact(s)
Mona Puggal, MPH
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0704
Email: mona.puggal@nih.gov

Financial/Grants Management Contact(s)

Leslye Fulwider
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-480-9544
Email: leslye.fulwider@nih.gov